CHFS vs. ELMD, QTI, NRXS, CUTR, VRAYQ, VIVE, ACOG, ENTA, SPRO, and IPHA
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Electromed (ELMD), QT Imaging (QTI), NeurAxis (NRXS), Cutera (CUTR), ViewRay (VRAYQ), Viveve Medical (VIVE), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Innate Pharma (IPHA).
Nuwellis vs. Its Competitors
Electromed (NYSE:ELMD) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.
In the previous week, Electromed's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.
Electromed presently has a consensus target price of $38.00, suggesting a potential upside of 96.89%. Given Electromed's stronger consensus rating and higher probable upside, equities analysts clearly believe Electromed is more favorable than Nuwellis.
Electromed has a net margin of 11.34% compared to Nuwellis' net margin of -254.26%. Electromed's return on equity of 15.71% beat Nuwellis' return on equity.
40.8% of Electromed shares are held by institutional investors. Comparatively, 65.1% of Nuwellis shares are held by institutional investors. 14.0% of Electromed shares are held by insiders. Comparatively, 0.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Electromed has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Electromed has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Summary
Electromed beats Nuwellis on 11 of the 14 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:CHFS) was last updated on 7/15/2025 by MarketBeat.com Staff
Free CHFS Stock Alerts